

# News Release



(For reference purpose only – Japanese version prevails in case of any discrepancy)

April 8, 2025

## Revision to Consolidated Earnings Forecast for the Fiscal Year Ending March 31, 2025

Kaken Pharmaceutical Co., Ltd. (“Kaken” or the “Company”, Head Office: Bunkyo-ku, Tokyo; President and Representative Director, Hiroyuki Horiuchi), announced today that the Company made the following revision to consolidated earnings forecast for the fiscal year ending March 31, 2025 (financial period from April 1, 2024 to March 31, 2025), which was disclosed on August 7, 2024, based on the current business performance.

### 1. Revision to consolidated earnings forecast

(Unit: millions of JPY)

	Net sales	Operating profit	Ordinary profit	Profit attributable to owners of the parent	Basic earnings per share (Yen)
Forecast announced previously (A)	88,500	20,800	21,200	14,200	374.97
Revised forecast (B)	94,000	20,800	21,000	14,000	364.55
Changes (B-A)	5,500	0	(200)	(200)	---
Percentage of changes (%)	6.2	0.0	(0.9)	(1.4)	---
(reference) Consolidated financial results for the previous period	72,044	9,513	9,951	8,025	212.67

### 2. Reason for revision to consolidated earnings forecast

The forecast for net sales has been revised upward from the previously announced forecast to reflect the receipt of an upfront payment as described in the press release “KAKEN Entered into a License Agreement for STAT6 Inhibitor” announced on December 26, 2024, and other factors.

Operating profit, ordinary profit, and profit attributable to owners of the parent have been partially revised to reflect the upfront payment as described in the press release “Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan” announced on March 25, 2025, as well as the expenses described in the press release “Notice of Completion of Acquisition of Aadi Subsidiaries, Inc, U.S.A.” announced on March 27, 2025.

### Cautionary notes regarding forward-looking statement

*This release contains forward-looking statements on the Kaken group’s business. They are projections based on information available at the time this release was prepared, and may differ from actual results due to a variety of factors.*